Caribou Biosciences


Clinical-stage biopharmaceutical company developing genome-edited allogeneic (off-the-shelf) cell therapies. The organization focuses on next-generation CRISPR guide design that combines RNA and DNA components to improve editing specificity and enable multiplex, site-specific edits. Programs include allogeneic CAR-T and CAR-NK approaches engineered for immune evasion and enhanced activity, and clinical development includes Phase 1 studies in hematologic malignancies.

Industries

Biotechnology
Health Care
Oncology
Therapeutics
Biotechnology Research

Nr. of Employees

medium (51-250)

Caribou Biosciences


Patents

Compositions and methods of nucleic acid-targeting nucleic acids

US-12686865-B2

View Details

Dual guide CRISPR hybrid DNA/RNA polynucleotides and methods of use

US-12644138-B2

View Details

Anti-ROR1 antibody and ROR1-targeting engineered cells

US-12492264-B2

View Details

Humanized BCMA antibody and BCMA-CAR-T cells

US-12435152-B2

View Details

Method of capturing CRISPR endonuclease cleavage products

US-12416045-B2

View Details

Engineered cascade components and cascade complexes

US-12227776-B2

View Details
View All Patents

Products

Allogeneic anti-CD19 CAR-T with PD-1 knockout (clinical-stage, Phase 1)

Donor-derived, genome-edited CAR-T therapy with TRAC disruption, site-specific CAR insertion into TRAC, and PD-1 knockout intended for relapsed/refractory B cell non-Hodgkin lymphoma; developed as an off-the-shelf product to reduce manufacturing timelines and enhance antitumor activity.

Allogeneic anti-BCMA CAR-T with immune cloaking (clinical-stage, Phase 1)

Donor-derived CAR-T therapy engineered with multiple edits including TRAC disruption, CAR insertion, and B2M knock-out with B2M–HLA-E fusion insertion to reduce host immune rejection by T and NK cells; developed for relapsed/refractory multiple myeloma.

Allogeneic anti-CLL-1 CAR-T for acute myeloid leukemia (early clinical)

Genome-edited donor-derived CAR-T therapy targeting CLL-1 being evaluated in early-stage clinical studies for relapsed/refractory acute myeloid leukemia.

iPSC-derived allogeneic CAR-NK cell therapy (preclinical)

Induced pluripotent stem cell (iPSC)-derived, engineered CAR-NK cell therapy designed for enhanced activity against solid tumors (preclinical data reported).

CB-011

CB-011 is a genome-edited allogeneic anti-B cell maturation antigen (BCMA) CAR-T cell product candidate engineered with next-generation CRISPR technology to knock out B2M and express a B2M-HLA-E fusion transgene for the treatment of relapsed or refractory multiple myeloma.

Vispa-cel

Vispacabtagene regedleucel (vispa-cel, formerly CB-010) is a lead clinical-stage allogeneic anti-CD19 CAR-T cell therapy utilizing a PD-1 knockout to limit premature CAR-T cell exhaustion for the treatment of relapsed or refractory B-NHL.

View All Products

Expertise Areas

  • Genome editing platform development
  • Allogeneic cell therapy engineering
  • Clinical trial management for early-stage cell therapies
  • Immunoengineering and immune evasion strategies
  • Show More (3)

Key Technologies

  • Hybrid RNA–DNA CRISPR guides
  • Cas12a-mediated genome editing
  • Cas9-mediated genome editing
  • Multiplex genome editing
  • Show More (6)

News & Updates

Pre-publication draft describing Cas12a hybrid RNA-DNA-mediated in vivo genome editing for high-specificity functional gene disruption.

Presentation describing CB-011 with immune cloaking in patients with relapsed/refractory multiple myeloma presented at EHA 2026.

Presentation of Vispa-cel clinical results at EHA 2026.

Peer-reviewed article describing high-specificity CRISPR editing to suppress allograft rejection for anti-BCMA CAR-T in preclinical models.

Programs cited as having received or pursued Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.